PETER AHN: Open Payments
NPI 1568909901 · WINNETKA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$800 in 54 payments from 10 companies in 2025. Trend: 2023 $480 · 2024 $757 · 2025 $800
Food & beverage: $800
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $177 |
| Amgen Inc. | 34 | $176 |
| Lilly USA, LLC | 6 | $135 |
| AstraZeneca Pharmaceuticals LP | 1 | $116 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $62 |
| SHIELD THERAPEUTICS INC | 2 | $41 |
| Merck Sharp & Dohme LLC | 1 | $34 |
| SANOFI-AVENTIS U.S. LLC | 1 | $27 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
Products named: Wegovy, REPATHA, MOUNJARO, AIRSUPRA, Kerendia, ACCRUFER, OTEZLA, CAPVAXIVE.
Industry payments across CA — which companies pay providers there.
